Stephen Hanauer

Dr. Hanauer is the Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University’s Feinberg School of Medicine since 2014. Dr. Hanauer received his medical degree from the University of Illinois Chicago, and he completed his residency in internal medicine and a fellowship in gastroenterology at the University of Chicago in 1982. In 2014, Dr. Hanauer was named the Medical Director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine in the Northwestern University’s Feinberg School of Medicine, where he continues to treat IBD patients and conducts research into new therapies.

Dr. Hanauer is a Fellow and past President of the American College of Gastroenterology (ACG) and the former Chair of the American Gastroenterological Association’s Inflammation, Immunology, and IBD Section. In October 2020, received the Master of the American College of Gastroenterology.

Internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs. Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of most of the leading IBD therapies.

Dr. Hanauer has authored over 500 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials. He has been a reviewer for NEJM, Annals of Internal Medicine, Lancet, Gastroenterology and numerous specialty journals.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Dr. Jessica Allegretti currently serves as the Medical Director of the Crohn’s and Colitis Center at the Brigham and Women’s Hospital. In 2020, she received the Sherman Emerging Leader Prize for Excellence in Crohn’s and Colitis. In addition, she developed and leads the hospital’s Fecal Microbiota Transplantation Program and has grown to become and international expert on the topic. Dr. Allegretti cares for patients with inflammatory bowel disease as well as Clostridioides difficile (c.diff) infection. Her research focuses on the intestinal microbiome and the consequences of its derangement, with the goal of understanding the role dysbiosis plays in microbial associated diseases. In addition, her lab focuses on novel therapeutic agents for IBD and she is leading multiple sponsored and investigator initiated drug trials. For more information visit www.allegrettilab.com

Marla C. Dubinsky received a medical degree from Queen’s University in Canada and completed her clinical pediatric gastroenterology training at Sainte-Justine Hospital, University of Montreal in Quebec, Canada adn her IBD training at Cedars-SInai Medical Center, Los Angeles, CA. Dr. Dubinsky is a proud recipient of the 2022 Sherman Prize for Excellence in Crohn’s and Colitis and a 2024 Jacobi Medallion winner for her contibutions to Mount Sinai. Currently, Dr. Dubinsky is Chief of Pediatric Gastroenterology and Nutrition, as well as the Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center and Co-director of the Marie and Barry Lipman Preconception and Pregnancy Planning Clinic at Mount Sinai Hospital, New York, She is a Professor of both Pediatrics and Medicine at the Icahn School of Medicine, Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in over 400 peer reviewed journals including New England Journal of Medicine, Lancet, Gastroenterology, The American Journal of Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and of Crohn's and Colitis .

Professor Remo Panaccione is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Unit at the University of Calgary, Canada. He serves as the Dean of MD Admissions and Director of the IBD Fellowship Program. He also holds the Crohn’s Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease.

He is the 2020 Crohn's Colitis Canada Outstanding Physician of the Year and received the 2024 Crohn’s Colitis Canada Research Leadership Award for his contributions to the field. Since 2020 he has been a Clarivate Research Scholar for being cited in the top one percent of researchers in the world. He has co-authored over 500 manuscripts, 20 book chapters and 825 abstracts, including publications in journals such as the New England Journal of Medicine, The Lancet, JAMA, Nature, and Annals of Internal Medicine.

Prof. Panaccione’s main research interest is the design and implementation of clinical trials. He has been the principal investigator on several studies evaluating the efficacy and safety of new therapeutic agents in subjects with IBD.

Dr. Rieder is Vice Chair and Co-Director of the IBD section at the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic, Cleveland. His clinical focus is patients with IBD with a special emphasis on the field of pathogenesis, prediction and therapy of intestinal fibrosis. Dr. Rieder has published more than 200 articles and book chapters and has been recognized for his expertise as indicated through invitations to clinical guideline steering committees of the European Crohn’s and Colitis Organization (ECCO). He is lead author of the ECCO guidelines on Ulcerative colitis and lead author of the first ECCO clinical consensus on ‘Diagnosis and Management of Intestinal Fibrosis’. He received multiple international invitations as a speaker, session chair or conference faculty. Dr. Rieder serves as an abstract reviewer for all major GI conferences, he is past associate editor (Clinical and Translational Gastroenterology) and on several editorial boards of medical journals. He is proud of his significant ties to the ECCO, which he served as the chair of Y-ECCO, member of the ECCO operational board, prior Y-ECCO committee member and member of the scientific committee. He is past chair of REACH-IBD and Co-Chair of the Professional Education Committee of the Crohn’s and Colitis Foundation. Dr. Rieder is the leading PI on the international Stenosis Therapy and Research (STAR) Consortium with the goal to build a pathway to test anti-fibrotic medications in stricturing Crohn’s disease. He received the Sherman Emerging Leader Prize in 2019.

David T. Rubin is the Joseph B. Kirsner Professor of Medicine, Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology & Nutrition and Director of the Inflammatory Bowel Disease Center at the University of Chicago Medicine. He earned a medical degree with honors at The University of Chicago Pritzker School of Medicine where he also completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics. He is associate faculty member at the MacLean Center for Clinical Medical Ethics, associate investigator at the University of Chicago Comprehensive Cancer Center and a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the immediate past Chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation and Deputy Chair of the International Organization for the Study of IBD.
Dr. Rubin’s research is focused on disease modification in IBD including clinical trial designs, novel measures of inflammation and prevention of adverse outcomes, and quality of life in IBD. In 2023, he received both the UChicago Michael Reese Lectureship Award (for outstanding faculty who have developed novel teaching and clinical research that advances healthcare) and the distinguished UChicago Arthur H. Rubenstein Mentorship in Academic Medicine Award. Dr. Rubin is currently a senior editor of the 12 edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, and an author on >600 articles on management of IBD, including the 2019 and 2025 ACG Guidelines for ulcerative colitis.

Dr. Hanauer is the Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University’s Feinberg School of Medicine since 2014. Dr. Hanauer received his medical degree from the University of Illinois Chicago, and he completed his residency in internal medicine and a fellowship in gastroenterology at the University of Chicago in 1982. In 2014, Dr. Hanauer was named the Medical Director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine in the Northwestern University’s Feinberg School of Medicine, where he continues to treat IBD patients and conducts research into new therapies.

Dr. Hanauer is a Fellow and past President of the American College of Gastroenterology (ACG) and the former Chair of the American Gastroenterological Association’s Inflammation, Immunology, and IBD Section. In October 2020, received the Master of the American College of Gastroenterology.

Internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs. Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of most of the leading IBD therapies.

Dr. Hanauer has authored over 500 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials. He has been a reviewer for NEJM, Annals of Internal Medicine, Lancet, Gastroenterology and numerous specialty journals.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Corey A. Siegel, MD, MS, is the Director of the Walter and Carole Young Center for Digestive Health at the Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a Professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as chief medical resident. He then completed a fellowship in Gastroenterology at Dartmouth Hitchcock followed by a fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital in Boston.

Dr. Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, the Crohn’s and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and he received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

Dr Nayantara Coelho-Prabhu is Professor of Medicine at the Mayo Clinic in Rochester MN. She also currently serves as the ACG Governor for MN. Her research and clinical interests are in the detection and management of dysplasia in inflammatory bowel disease including advanced endoscopic imaging and resection techniques. She has extensive experience in management of gastrointestinal bleeding and advanced endoscopic therapies in the management of complications of IBD. She has published extensively in this field and mentored mutliple trainees. She also co-leads the artificial intelligence in endoscopy program at the Mayo Clinic Rochester, and is actively involved in the development and validation of endoscopy AI algorithms. The team she leads has developed a first-of its-kind digital endoscopy platform upon which further internal and external projects will exist. One of these already developed is a CADe for dysplastic lesions in IBD. She has spoken at multiple national and international meetings on these topics.

Dr. Grossman is the Associate Clinic Chief of Gastroenterology, Hepatology, and Nutrition and Co-Director of the Center for Pediatric Inflammatory Bowel Disease at the Children’s Hospital of Philadelphia and the Robert N. Baldassano MD Professor of Clinical Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Dr. Grossman has dedicated his career to advancing the quality of clinical care and promoting a multidisciplinary approach for children and adolescents with IBD. He has led national committees for the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and ImproveCareNow (ICN). He has been involved with the Crohn’s & Colitis Foundation for years, serving on the Board of Directors and the Chapter Medical Advisory Committee for the Philadelphia/Delaware Valley chapter, as well as serving as chair of the Pediatric Affairs Committee on the National Scientific Advisory Committee (NSAC). He has co-authored multiple research publications, is an editor of the Pediatric Inflammatory Bowel Disease textbook, and frequently lectures at national scientific meetings.

Dr. Hanauer is the Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University’s Feinberg School of Medicine since 2014. Dr. Hanauer received his medical degree from the University of Illinois Chicago, and he completed his residency in internal medicine and a fellowship in gastroenterology at the University of Chicago in 1982. In 2014, Dr. Hanauer was named the Medical Director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine in the Northwestern University’s Feinberg School of Medicine, where he continues to treat IBD patients and conducts research into new therapies.

Dr. Hanauer is a Fellow and past President of the American College of Gastroenterology (ACG) and the former Chair of the American Gastroenterological Association’s Inflammation, Immunology, and IBD Section. In October 2020, received the Master of the American College of Gastroenterology.

Internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs. Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of most of the leading IBD therapies.

Dr. Hanauer has authored over 500 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials. He has been a reviewer for NEJM, Annals of Internal Medicine, Lancet, Gastroenterology and numerous specialty journals.

Paulo Gustavo Kotze is Adjunct Senior Professor of Surgery at the Catholic University in Curitiba, Paraná, Brazil. He rcompleted his General Surgery training at the Evangelical University Hospital in Curitiba (2000). He also completed his senior Fellowship in Colorectal Surgery at the Clinics Hospital from the Federal University of Parana (2002). Dr. Kotze achieved his Masters' Degree on Surgery at the Catholic University in 2008 and joined the faculty of medicine at the same university in 2011. He achieved his PhD degree studying the influence of biological therapy on surgical outcomes in Crohn´s disease, in the University of Campinas, in São Paulo, Brazil (UNICAMP) in 2015. Dr. Kotze was also an IBD advanced visiting fellow in the IBD unit at the University of Calgary (Cumming school of medicine), Canada, for the period of 2017-2018. Dr. Kotze is an experienced IBD surgeon and author of 3 books, 250+ pubmed peer-reviewed articles and multiple book chapters focused on Crohn´s disease and ulcerative colitis. He has special interest in the fields of biological therapy, epidemiology and surgery in IBD. Dr. Kotze was formely a committee member of S-ECCO (surgeons of ECCO) from 2015-2018 and a member of the ECCO EduCOM (educational committee), 2018-2021. He is an active member from the International Organization of Inflammatory Bowel Diseases (IOIBD). Currently, he is Professor of the Health Sciences Postgraduate Program at the Catholic University of Paraná, in Curitiba, Brazil. Dr Kotze is also a senior researcher for the National Brazilian Council of Research (CNPq).

Dr. Hanauer is the Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University’s Feinberg School of Medicine since 2014. Dr. Hanauer received his medical degree from the University of Illinois Chicago, and he completed his residency in internal medicine and a fellowship in gastroenterology at the University of Chicago in 1982. In 2014, Dr. Hanauer was named the Medical Director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine in the Northwestern University’s Feinberg School of Medicine, where he continues to treat IBD patients and conducts research into new therapies.

Dr. Hanauer is a Fellow and past President of the American College of Gastroenterology (ACG) and the former Chair of the American Gastroenterological Association’s Inflammation, Immunology, and IBD Section. In October 2020, received the Master of the American College of Gastroenterology.

Internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs. Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of most of the leading IBD therapies.

Dr. Hanauer has authored over 500 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials. He has been a reviewer for NEJM, Annals of Internal Medicine, Lancet, Gastroenterology and numerous specialty journals.

Neilanjan Nandi, MD, FACG, AGAF, FCCF, FACP is an Associate Professor of Clinical Medicine at the Perelman School of Medicine, University of Pennsylvania and is the Co-Section Head and Direcotr of Clinical Operations of the University of Pennsylvania Inflammatory Bowel Disease Program. Dr. Nandi specializes in the complex management of Crohn's disease, Ulcerative Colitis and recurrent C. difficile infection (C difficile). He has also authored numerous abstracts, publications and book chapters on the diagnosis and management of IBD, C difficile and various viral, parasitic, mycobacterial and bacterial infections of the GI tract. Aligning with his interests, Dr. Nandi has conducted several clinical trials focused on the clinical impact of stool derived microbiome therapies in C difficile and IBD. Dr. Nandi servies on the Philadelphia/Delaware Valley Crohn's & Colitis Foundation (CCF) Executive Council and on the Medical Advisory Board of the United Ostomy Associates of America (UOAA). He is a founding non-profit board member and Chair of the South Asian IBD Alliance (SAIA) which elevates culturally competent care in South Asian IBD. He has been recognized with the 2019 Philly Take STeps Physician Hero, the 2022 CCF's National Chairman’s Citation Award and the 2024 CCF's Gold Medallion Physician Award. He is the honored recipient of the 2023 Sidney Cohen GI Faculty Teaching Award and the 2024 Radhika Srinivasan GI Faculty award for Professionalism and Humanism at the Perelman School of Medicine.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.